ArticleClinical endocrinology2012
Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size.
Article in Clinical endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.The Journal of clinical endocrinology and metabolism · 2014Trial
- Alterations of lipoprotein subfractions in GH-deficient adults.Frontiers in endocrinology · 2025Article
- Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity.BioMed research international · 2020Article
- Observational
- Reduced peak stimulated growth hormone is associated with hyperuricemia in obese children and adolescents.Scientific reports · 2018Article
- Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency.Lipids in health and disease · 2018Article
- Slim Body Weight Is Highly Associated With Enhanced Lipoprotein Functionality, Higher HDL-C, and Large HDL Particle Size in Young Women.Frontiers in endocrinology · 2018Article
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2015Review
- Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2014Article
- The vitamin D status of prison inmates.PloS one · 2014Article
- Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches.Nutrients · 2013Review
- The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity.The open cardiovascular medicine journal · 2012Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveReduced growth hormone (GH) secretion is observed in obesity and may contribute to increases in cardiovascular disease (CVD) risk. Lipoprotein characteristics including increased small dense low-density lipoprotein (LDL) particles are known independent risk factors for CVD. We hypothesized that reduced GH secretion in obesity would be associated with a more atherogenic lipid profile including increased small dense LDL particles.
designTo evaluate this hypothesis, we studied 102 normal weight and obese men and women using standard GH stimulation testing to assess GH secretory capacity and performed comprehensive lipoprotein analyses including determination of lipoprotein particle size and subclass concentrations using proton NMR spectroscopy.
resultsObese subjects were stratified into reduced or sufficient GH secretion based on the median peak-stimulated GH (≤6·25 μg/l). Obese subjects with reduced GH secretion (n = 35) demonstrated a smaller mean LDL and HDL particle size in comparison to normal weight subjects (n = 33) or obese subjects with sufficient GH (n = 34) by ANOVA (P < 0·0001). Univariate analyses demonstrated peak-stimulated GH was positively associated with LDL (r = 0·50; P < 0·0001) and HDL (r = 0·57; P < 0·0001), but not VLDL (P = 0·06) particle size. Multivariate regression analysis controlling for age, gender, race, ethnicity, tobacco, use of lipid-lowering medication, BMI and HOMA demonstrated peak-stimulated GH remained significantly associated with LDL particle size (β = 0·01; P = 0·01; R(2) = 0·42; P < 0·0001 for overall model) and HDL particle size (β = 0·008; P = 0·001; R(2) = 0·44; P < 0·0001 for overall model).
conclusionsThese results suggest reduced peak-stimulated GH in obesity is independently associated with a more atherogenic lipoprotein profile defined in terms of particle size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.